The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 08, 2016

Filed:

Oct. 26, 2012
Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Christopher James Bungard, Lansdale, PA (US);

Antonella Converso, Elkins Park, PA (US);

Barbara Hanney, Pennsburg, PA (US);

Timothy John Hartingh, Blue Bell, PA (US);

Peter J. Manley, Harleysville, PA (US);

Robert S. Meissner, Newton, MA (US);

James J. Perkins, Chruchville, PA (US);

Michael T. Rudd, Collegeville, PA (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 413/14 (2006.01); C07D 401/06 (2006.01); C07D 401/14 (2006.01); C07D 215/48 (2006.01); C07D 401/04 (2006.01); C07D 409/04 (2006.01); C07D 413/06 (2006.01); C07D 417/06 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 491/10 (2006.01);
U.S. Cl.
CPC ...
C07D 413/14 (2013.01); C07D 401/06 (2013.01); C07D 215/48 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 409/04 (2013.01); C07D 413/06 (2013.01); C07D 417/06 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 491/10 (2013.01);
Abstract

The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, R, -L-, R, n, R, and Rare as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.


Find Patent Forward Citations

Loading…